New surgical options are only as good as they make you feel once you leave the operating room. One of the biggest post-operative issues with the usually sound transaortic valve replacements (TAVR) was that the newly inserted valve allowed leakage that created poor outcomes.
University Hospitals announced that its surgeons completed the first commercial implant in the United States of the newly FDA approved TAVR valve called the CoreValve™
PRO for the treatment of severe symptomatic aortic stenosis. Recently unveiled clinical data showed high survival, low rates of stroke, minimal paravalvular leak (PVL) and excellent hemodynamics for the self-expanding valve.
The Evolut PRO device features a unique valve design with an outer wrap that adds surface area contact between the valve and the native aortic annulus to further advance valve sealing performance. The biocompatible porcine pericardial tissue wrap, in addition to other design elements, is incorporated to address the occurrence of blood leaking through the sides of the valve.
Download full release